Lucy To - 12 Aug 2024 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
Chief Financial Officer
Signature
/s/ Lucy To
Issuer symbol
SABS
Transactions as of
12 Aug 2024
Net transactions value
$0
Form type
4
Filing time
13 Aug 2024, 17:00:06 UTC
Previous filing
31 Jul 2024
Next filing
28 Aug 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SABS Employee Stock Option (right to buy) Award $0 +125,000 $0.000000 125,000 12 Aug 2024 Common Stock 125,000 $2.35 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan, as amended.
F2 The shares underlying the option vest over a four-year period, with 1/4 vesting on the one-year anniversary date from the Reporting Person's commencement of service as Chief Financial Officer (August 12, 2025), and the remainder vesting thereafter in equal monthly installments over a three year period.

Remarks:

Chief Financial Officer